Methods and strategies for assessing uncontrolled drug–drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group Peter L. BonateMalidi AhamadiJanet R. Wade Commentary 02 February 2016 Pages: 123 - 135
A strategy for residual error modeling incorporating scedasticity of variance and distribution shape Anne-Gaëlle DosneMartin BergstrandMats O. Karlsson Original Paper Open access 17 December 2015 Pages: 137 - 151
Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects Rashmi MehtaMichelle GreenJonathan Wagg Original Paper 06 January 2016 Pages: 153 - 164
Determination of a suitable voriconazole pharmacokinetic model for personalised dosing David A. J. McDougallJennifer MartinBruce Green Original Paper 16 December 2015 Pages: 165 - 177
Organ data from the developing Göttingen minipig: first steps towards a juvenile PBPK model Els Van PeerNoel DownesSteven Van Cruchten Original Paper 19 December 2015 Pages: 179 - 190
Model-based meta-analysis for development of a population-pharmacokinetic (PPK) model for Vitamin D3 and its 25OHD3 metabolite using both individual and arm-level data Alanna S. Ocampo-PellandMarc R. GastonguayMatthew M. Riggs Original Paper 12 February 2016 Pages: 191 - 206
Input estimation for drug discovery using optimal control and Markov chain Monte Carlo approaches Magnus TrägårdhMichael J. ChappellPeter Gennemark Original Paper Open access 01 March 2016 Pages: 207 - 221
Accelerating Monte Carlo power studies through parametric power estimation Sebastian UeckertMats O. KarlssonAndrew C. Hooker Original Paper Open access 02 March 2016 Pages: 223 - 234